7444.T
The company operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products and medical research services.
Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products and medical research services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products and medical research services.
The company maintains a strong liquidity position, with a current ratio of 2.04 and cash and equivalents amounting to ¥3.58 billion. However, the company reported negative free cash flow of ¥1.95 billion, indicating that capital expenditures exceeded operating cash flow. The price-to-book ratio of 0.42 suggests that the company is trading at a significant discount to its book value, which may reflect market concerns about its asset quality or future earnings potential.
In terms of profitability, the company's return on equity (ROE) of 5.2% and return on assets (ROA) of 3.55% are below the industry median for pharmaceutical companies, which typically report ROE in the 10-15% range. The company's operating margin is also weak, with operating income of ¥1.91 billion on revenue of ¥61.82 billion, translating to a margin of 3.1%. This is significantly lower than the industry median of 15-20%.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to regional economic and regulatory risks. The company's revenue is entirely derived from its pharmaceutical and medical research operations, with no material contribution from other business lines.
Looking ahead, the company's revenue is expected to remain relatively flat, with no significant growth anticipated in the next fiscal year. The company's capital expenditures are expected to remain high, driven by ongoing investments in research and development. The company's free cash flow is expected to remain negative in the near term, as capital expenditures continue to outpace operating cash flow.
The company's risk profile is characterized by low liquidity and dilution risk. The company has no immediate filing-based liquidity or dilution flags, and its debt-to-equity ratio of 0.1 indicates a conservative capital structure. However, the company's negative free cash flow and high capital expenditures may increase its reliance on external financing in the future, which could introduce dilution risk.
Recent events, including the company's latest financial filings and investor relations disclosures, indicate a stable operating environment. The company has not disclosed any material legal or regulatory issues, and its recent earnings and revenue figures align closely with analyst estimates. The company's management has not indicated any major strategic shifts or restructuring plans in the near term.
- The company has a strong liquidity position but is generating negative free cash flow due to high capital expenditures.
- The company's profitability metrics, including ROE and operating margin, are below industry medians.
- The company's revenue is concentrated in a single business segment with no geographic diversification.
- The company's capital structure is conservative, with low debt and no immediate dilution risk.
- The company's revenue is expected to remain flat in the near term, with no significant growth anticipated.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 7444.T Market data — financials · 2026-05-27
- Harima-Kyowa Co Ltd Market data — analyst estimates · 2026-05-27